Coastal Infusion Administers Opdualag™
| J-Code | J9298 |
|---|---|
| Manufacturer | Bristol-Myers Squibb |
| First Approved | 03/18/2022 |
Coastal Infusion can administer your Opdualag prescription at any of our south Florida locations.
Opdualag (nivolumab and relatlimab-rmbw) is used as a first-line treatment for melanoma that has spread or cannot be surgically removed.
The active substances in Opdualag, nivolumab and relatlimab, are monoclonal antibodies. Cancer cells can produce proteins (PD-L1 and PD-L2) on their surface that attach to the PD-1 receptor and switch off the activity of the T cells, preventing them from attacking the cancer. By attaching to the receptor, nivolumab prevents PD-L1 and PD-L2 from switching off the T cells, thereby increasing the ability of the immune system to kill cancer cells. Relatlimab attaches to and blocks another receptor known as LAG-3.
What It Treats
Opdualag is used as a first-line treatment for melanoma.
Prescribed By
Opdualag is most often prescribed by Oncologists and Dermatologists.
How it’s Administered
Opdualag is administered by intravenous infusion. Opdualag infusions take about 30 minutes.
Frequency
Opdualag is generally administered every four weeks.
Related Drugs
Additional Resources
The information on this page is compiled from a variety of online sources. Coastal Infusion has made every effort to verify its accuracy, but patients are advised to discuss any planned or current treatments with their doctor. Report inaccuracies